查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1581287

標靶治療市場：按類型、作用機制、分銷管道和治療領域分類 - 全球預測 2025-2030

Targeted Therapy Market by Type (Monoclonal Antibodies, Small Molecule Medicines), Mechanism of Action (Angiogenesis Inhibitors, Apoptosis Inducers, Gene Expression Modulators), Distribution Channel, Therapeutic Area - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年標靶治療市場估值為627.5億美元，預計2024年將達671.6億美元，複合年成長率為7.44%，到2030年將達到1037.5億美元。

標靶治療是一種創新的癌症治療形式，它使用藥物或其他物質來精確識別和攻擊癌細胞，通常不會傷害正常細胞。這種方法需要深入了解癌症的分子和遺傳基礎，並針對參與腫瘤生長和進展的特定分子。應用包括多種癌症類型，並且越來越重視個人化醫療，根據個人的基因譜提供量身定做的治療。最終使用領域包括醫院腫瘤科、專業癌症治療中心和研究機構。

主要市場統計
基準年[2023] 627.5億美元
預測年份 [2024] 671.6億美元
預測年份 [2030] 1037.5億美元
複合年成長率（%） 7.44%

根據市場洞察，標靶治療的成長受到癌症發病率上升、基因組技術進步以及精準醫療需求不斷成長的顯著影響。政府對癌症研究的支持進一步推動了這個市場。公司不斷創新，旨在提高治療的特異性和有效性，同時最大限度地減少副作用。最新的商機在於開發新型生物標記和伴同性診斷，以推動個人化治療計劃。為了利用這些機會，公司需要投資研發合作並擴大其藥物管道組合。

然而，挑戰依然存在，包括高昂的開發和治療成本、監管障礙以及複雜的臨床試驗流程。此外，可能會對標靶治療治療產生抗藥性，從而降低長期療效。腫瘤遺傳學的複雜性也為精確定位標靶帶來了挑戰，需要繼續研究和完善現有的治療方法。

創新和研究工作應著重於擴大現有療法的適應症、探索協同聯合治療以及利用人工智慧進行藥物發現。由於市場競爭激烈且充滿活力，企業必須保持適應能力，強調持續創新和以市場為導向的研究以維持成長。簡而言之，市場的本質要求敏捷性，企業需要快速適應技術進步和不斷變化的消費者需求，以保持競爭力。

市場動態：揭示快速發展的標靶治療市場的關鍵市場洞察

供給和需求的動態相互作用正在改變標靶治療市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 全球癌症易感性盛行率不斷增加
    • 增加整個全部區域藥物開發的投資
    • 改善癌症治療的法律規範和指南
  • 市場限制因素
    • 治療高成本
  • 市場機會
    • 日益關注個人化醫療的聯合治療
    • 使用次世代定序儀(NGS) 和 CRISPR 的基因分析技術的進步
  • 市場挑戰
    • 患者對標靶治療的反應存在差異

波特五力：開拓標靶治療市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解標靶治療市場的外部影響

外部宏觀環境因素在塑造標靶治療市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解標靶治療市場的競爭格局

標標靶治療市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的見解，以應對日益激烈的競爭。

FPNV定位矩陣標標靶治療市場供應商績效評估

FPNV定位矩陣是評估標靶治療市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議繪製標靶治療市場的成功之路

標靶治療市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球癌症發生率上升
      • 各地區藥物開發投資增加
      • 改善癌症治療的法規結構和指南
    • 抑制因素
      • 治療費用高
    • 機會
      • 日益關注個人化醫療的聯合治療
      • 用於基因結構分析的次世代定序(NGS) 和 CRISPR 技術進步
    • 任務
      • 患者對標靶治療的反應存在差異
  • 市場區隔分析
    • 類型：擴大單株抗體在個人化醫療中的使用
    • 治療領域：肺癌治療快速推廣，投資龐大
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章標靶治療市場：依類型

  • 單株抗體
  • 小分子藥物

第7章依作用機轉分類的標靶治療市場

  • 血管新生抑制劑
  • 細胞凋亡誘導劑
  • 基因表現因子
  • 荷爾蒙療法
  • 訊號傳導抑制劑

第8章標靶治療市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第9章按治療領域標靶治療市場

  • 乳癌
  • 大腸直腸癌
  • 白血病
  • 肺癌
  • 淋巴瘤
  • 多發性硬化症
  • 腎癌

第10章美洲標靶治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太標標靶治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲標靶治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • 諾華收購 Mariana Oncology 加強癌症治療手段
    • 德爾菲亞生物技術公司推出標靶和殺死癌細胞的創新方法
    • 諾華在印度推出治療慢性骨髓性白血病的新藥，為患者提供更好的治療選擇
  • 戰略分析和建議

公司名單

  • AbbVie Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • BeiGene, Ltd.
  • Biogen Inc.
  • BioMarin Pharmaceutical Inc.
  • Bristol Myers Squibb Company
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Exelixis, Inc.
  • F. Hoffmann-La Roche AG
  • Genmab A/S
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Incyte Corporation
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-CA7E340319CF

The Targeted Therapy Market was valued at USD 62.75 billion in 2023, expected to reach USD 67.16 billion in 2024, and is projected to grow at a CAGR of 7.44%, to USD 103.75 billion by 2030.

Targeted therapy is an innovative form of cancer treatment that uses drugs or other substances to precisely identify and attack cancer cells, usually without harming normal cells. This approach necessitates a deep understanding of the molecular and genetic bases of cancer, targeting specific molecules involved in tumor growth and progression. Applications range across various types of cancers, with a growing emphasis on personalized medicine, where treatments are tailored to individual genetic profiles. End-use sectors prominently include oncology departments in hospitals, specialized cancer treatment centers, and research institutions.

KEY MARKET STATISTICS
Base Year [2023] USD 62.75 billion
Estimated Year [2024] USD 67.16 billion
Forecast Year [2030] USD 103.75 billion
CAGR (%) 7.44%

Market insights reveal targeted therapy's growth is significantly influenced by rising cancer prevalence, advances in genomic technologies, and increasing demand for precision medicine. Government support for cancer research further bolsters this market. Companies are consistently innovating, aiming to improve the specificity and efficacy of treatments while minimizing side effects. The latest opportunities lie in the development of novel biomarkers and companion diagnostics, propelling personalized treatment plans. To capitalize on these opportunities, firms should invest in R&D collaborations and broaden their drug pipeline portfolios.

However, challenges persist, such as the high costs of development and treatment, regulatory hurdles, and complex clinical trial processes. Additionally, resistance to targeted therapies can develop, leading to reduced long-term efficacy. The intricacies of tumor genetics also pose challenges in accurately identifying targets, necessitating ongoing research and refinement of existing therapies.

Innovation and research efforts should focus on expanding indications for existing therapies, exploring synergistic combination treatments, and leveraging artificial intelligence for drug discovery. As the market is highly competitive and dynamic, businesses must remain adaptable, emphasizing continuous innovation and market-oriented research to sustain growth. In essence, the nature of the market demands agility, with companies needing to swiftly adapt to technological advancements and evolving consumer demands to maintain a competitive edge.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Targeted Therapy Market

The Targeted Therapy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of cancer susceptibility globally
    • Rising investment in drug development across geographies
    • Improved regulatory frameworks and guidelines for cancer treatment
  • Market Restraints
    • High cost associated with treatment
  • Market Opportunities
    • Increased focus on combination therapies for personalized medicine
    • Technological advancements in next-generation sequencing (NGS) and CRISPR for genetic makeup
  • Market Challenges
    • Variability in patient response to targeted therapies

Porter's Five Forces: A Strategic Tool for Navigating the Targeted Therapy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Targeted Therapy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Targeted Therapy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Targeted Therapy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Targeted Therapy Market

A detailed market share analysis in the Targeted Therapy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Targeted Therapy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Targeted Therapy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Targeted Therapy Market

A strategic analysis of the Targeted Therapy Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Targeted Therapy Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, BeiGene, Ltd., Biogen Inc., BioMarin Pharmaceutical Inc., Bristol Myers Squibb Company, Eisai Co., Ltd., Eli Lilly and Company, Exelixis, Inc., F. Hoffmann-La Roche AG, Genmab A/S, Gilead Sciences, Inc., GlaxoSmithKline plc, Incyte Corporation, Johnson & Johnson Services, Inc., Merck & Co., Inc., Merck KGaA, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sanofi S.A., and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Targeted Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Monoclonal Antibodies and Small Molecule Medicines.
  • Based on Mechanism of Action, market is studied across Angiogenesis Inhibitors, Apoptosis Inducers, Gene Expression Modulators, Hormone Therapies, and Signal Transduction Inhibitors.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Therapeutic Area, market is studied across Breast Cancer, Colorectal Cancer, Leukemia, Lung Cancer, Lymphoma, Multiple Sclerosis, and Renal Cancer.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of cancer susceptibility globally
      • 5.1.1.2. Rising investment in drug development across geographies
      • 5.1.1.3. Improved regulatory frameworks and guidelines for cancer treatment
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Increased focus on combination therapies for personalized medicine
      • 5.1.3.2. Technological advancements in next-generation sequencing (NGS) and CRISPR for genetic makeup
    • 5.1.4. Challenges
      • 5.1.4.1. Variability in patient response to targeted therapies
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Expanding usage of monoclonal antibodies for personalized medicine
    • 5.2.2. Therapeutic Area: Rapid adoption of lung cancer therapies with substantial investment
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Targeted Therapy Market, by Type

  • 6.1. Introduction
  • 6.2. Monoclonal Antibodies
  • 6.3. Small Molecule Medicines

7. Targeted Therapy Market, by Mechanism of Action

  • 7.1. Introduction
  • 7.2. Angiogenesis Inhibitors
  • 7.3. Apoptosis Inducers
  • 7.4. Gene Expression Modulators
  • 7.5. Hormone Therapies
  • 7.6. Signal Transduction Inhibitors

8. Targeted Therapy Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Hospital Pharmacies
  • 8.3. Online Pharmacies
  • 8.4. Retail Pharmacies

9. Targeted Therapy Market, by Therapeutic Area

  • 9.1. Introduction
  • 9.2. Breast Cancer
  • 9.3. Colorectal Cancer
  • 9.4. Leukemia
  • 9.5. Lung Cancer
  • 9.6. Lymphoma
  • 9.7. Multiple Sclerosis
  • 9.8. Renal Cancer

10. Americas Targeted Therapy Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Targeted Therapy Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Targeted Therapy Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Novartis Strengthens Cancer Treatment Arsenal with Acquisition of Mariana Oncology
    • 13.3.2. Delphia Biotech Introduces Launched a Revolutionary Approach Targeting and Killing Cancer Cells
    • 13.3.3. Novartis to Launch New Chronic Myeloid Leukemia Drug in India, Offering Improved Treatment Options for Patients
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Amgen Inc.
  • 3. Astellas Pharma Inc.
  • 4. AstraZeneca PLC
  • 5. Bayer AG
  • 6. BeiGene, Ltd.
  • 7. Biogen Inc.
  • 8. BioMarin Pharmaceutical Inc.
  • 9. Bristol Myers Squibb Company
  • 10. Eisai Co., Ltd.
  • 11. Eli Lilly and Company
  • 12. Exelixis, Inc.
  • 13. F. Hoffmann-La Roche AG
  • 14. Genmab A/S
  • 15. Gilead Sciences, Inc.
  • 16. GlaxoSmithKline plc
  • 17. Incyte Corporation
  • 18. Johnson & Johnson Services, Inc.
  • 19. Merck & Co., Inc.
  • 20. Merck KGaA
  • 21. Novartis AG
  • 22. Pfizer Inc.
  • 23. Regeneron Pharmaceuticals, Inc.
  • 24. Sanofi S.A.
  • 25. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. TARGETED THERAPY MARKET RESEARCH PROCESS
  • FIGURE 2. TARGETED THERAPY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL TARGETED THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL TARGETED THERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES TARGETED THERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES TARGETED THERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. TARGETED THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. TARGETED THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. TARGETED THERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL TARGETED THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL TARGETED THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. TARGETED THERAPY MARKET DYNAMICS
  • TABLE 7. GLOBAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE MEDICINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL TARGETED THERAPY MARKET SIZE, BY ANGIOGENESIS INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL TARGETED THERAPY MARKET SIZE, BY APOPTOSIS INDUCERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL TARGETED THERAPY MARKET SIZE, BY GENE EXPRESSION MODULATORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL TARGETED THERAPY MARKET SIZE, BY HORMONE THERAPIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL TARGETED THERAPY MARKET SIZE, BY SIGNAL TRANSDUCTION INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL TARGETED THERAPY MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL TARGETED THERAPY MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL TARGETED THERAPY MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL TARGETED THERAPY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL TARGETED THERAPY MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL TARGETED THERAPY MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL TARGETED THERAPY MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL TARGETED THERAPY MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL TARGETED THERAPY MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL TARGETED THERAPY MARKET SIZE, BY RENAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES TARGETED THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. AUSTRALIA TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 61. AUSTRALIA TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 62. AUSTRALIA TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. CHINA TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 65. CHINA TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 66. CHINA TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. INDIA TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 69. INDIA TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 70. INDIA TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. INDONESIA TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 73. INDONESIA TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 74. INDONESIA TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. JAPAN TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 77. JAPAN TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 78. JAPAN TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. MALAYSIA TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 81. MALAYSIA TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 82. MALAYSIA TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. PHILIPPINES TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 85. PHILIPPINES TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 86. PHILIPPINES TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. SINGAPORE TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 89. SINGAPORE TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 90. SINGAPORE TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. SOUTH KOREA TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 93. SOUTH KOREA TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 94. SOUTH KOREA TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. TAIWAN TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 97. TAIWAN TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 98. TAIWAN TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. THAILAND TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 101. THAILAND TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 102. THAILAND TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. VIETNAM TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 105. VIETNAM TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 106. VIETNAM TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. DENMARK TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 114. DENMARK TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 115. DENMARK TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. EGYPT TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 118. EGYPT TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 119. EGYPT TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. FINLAND TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 122. FINLAND TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 123. FINLAND TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. FRANCE TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 126. FRANCE TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 127. FRANCE TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. GERMANY TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 130. GERMANY TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 131. GERMANY TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. ISRAEL TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 134. ISRAEL TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 135. ISRAEL TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. ITALY TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 138. ITALY TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 139. ITALY TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. NETHERLANDS TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 142. NETHERLANDS TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 143. NETHERLANDS TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. NIGERIA TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 146. NIGERIA TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 147. NIGERIA TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. NORWAY TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 150. NORWAY TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 151. NORWAY TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. POLAND TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 154. POLAND TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 155. POLAND TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. QATAR TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 158. QATAR TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 159. QATAR TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. RUSSIA TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 162. RUSSIA TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 163. RUSSIA TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. SAUDI ARABIA TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 166. SAUDI ARABIA TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 167. SAUDI ARABIA TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH AFRICA TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 170. SOUTH AFRICA TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 171. SOUTH AFRICA TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. SPAIN TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 174. SPAIN TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 175. SPAIN TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. SWEDEN TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 178. SWEDEN TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 179. SWEDEN TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. SWITZERLAND TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 182. SWITZERLAND TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 183. SWITZERLAND TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. TURKEY TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 186. TURKEY TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 187. TURKEY TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED ARAB EMIRATES TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED ARAB EMIRATES TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED ARAB EMIRATES TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. UNITED KINGDOM TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 194. UNITED KINGDOM TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 195. UNITED KINGDOM TARGETED THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 196. TARGETED THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 197. TARGETED THERAPY MARKET, FPNV POSITIONING MATRIX, 2023